Metastatic CRC Progressing on Multiple Therapies

Video

Metastatic CRC Progressing on Multiple Therapies

October 2015

  • A 64-year-old woman underwent left hemicolectomy for an obstructing mass at the rectosigmoid junction
    • CEA were elevated, 23.3 ng/mL
    • Pathology showed an undifferentiated adenocarcinoma, invading through the muscularis mucosae up to the pericolic fat; 14 nodes were biopsied, 10 of which were metastatic
    • Imaging with PET/CT showed several lung lesions, three measuring up to 3.0 cm in size
    • Mutational status was both RAS and BRAF wild-type
    • Microsatellite stable
    • Diagnosis; high grade colorectal adenocarcinoma, stage T4N2M1
  • PMH includes arterial hypertension, well-controlled on an ACE inhibitor and coronary angioplasty with stent placement 4 years ago
  • The patient received systemic therapy with FOLFIRI + cetuximab; grade 1 rash and grade 2 thrombocytopenia were managed with dose adjustment of FOLFIRI
  • Follow-up imaging at 2 months and 4 months showed significant response in the lung lesions
  • The patient was continued on maintenance therapy with cetuximab

August 2016

  • The patient complains of weight loss, nausea and fatigue
  • CT of the chest, abdomen, and pelvis showed marked progression in 2 of the lung lesions and development of new liver lesions
  • The patient was switched to CAPEOX with bevacizumab. Her blood pressure was closely monitored and remained stable
  • Follow up imaging at 2 months and at 4 months showed stable disease in the lung and liver lesions and improvement of her symptoms
  • At 4 months, oxaliplatin was discontinued; maintenance therapy with capecitabine and bevacizumab was continued

January 2017

  • At 5 months, the patient reports having reappearance of her symptoms, although she continues her normal physical activity
  • CEA level is rising significantly
  • Follow up CT showed further progressive disease in the lung and the appearance of several small boney lesions
  • The patient is motivated to try another therapy and has opted for regorafenib
Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
Related Content